Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
PR Newswire —
Initial Phase 1 data from Verismo's STAR-101 clinical trial assessing SynKIR™-110 in mesothelin-expressing solid tumors to be released in oral late-breaking presentation; preclinical and initial Phase 1 data from CELESTIAL-301 assessing SynKIR™-310 in B cell Non-Hodgkin Lymphoma to be...